Skip to main content
Fig. 2 | Molecular Cancer

Fig. 2

From: AMPK promotes antitumor immunity by downregulating PD-1 in regulatory T cells via the HMGCR/p38 signaling pathway

Fig. 2

AMPK deficiency in Tregs upregulates the expression of PD-1. Bar diagram representation of flow cytometric analysis of relative mean fluorescence intensities (MFI) of PD-1, CTLA-4, Nrp1, ICOS, GITR, OX40, CD73, and CD39 in Tregs A gated from splenocytes of tumor-free mice and B gated from tumor-infiltrated lymphocytes. MFI of PD-1, Nrp1, and ICOS in splenic Tregs from WT mice after treatment with C compound C or D AICAR for 24 h. E Immunoblot analysis of PD-1 in Tregs treated with AICAR and compound C at the indicated doses and times of stimulation with anti-CD3/CD28. F T cell suppression assays with WT and AMPK-KO Tregs. G Bar diagram representation of flow cytometric analysis of IL-10-expressing WT and AMPK-KO Tregs and qRT-PCR results of the Il-10 mRNA levels. H MFI of TGF-β-expressing WT and AMPK- KO Tregs and qRT-PCR results of the Tgf-β mRNA levels. The data are presented as the mean ± standard deviation (SD); n = 5 mice per group. *P < 0.05; **P < 0.01; ***P < 0.001

Back to article page